Istituto Romagnolo per lo Studio dei Tumori, Dino Amadori

Meldola 47014

3 studies enrolling now · 14 studies all time

What they study most

Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Adult Disease, Advanced Breast Cancer, Advanced Gastrointestinal Stromal Tumors, Advanced Solid Tumor, Chronic Lymphocytic Leukemia, Cutaneous Melanoma, ET (Essential Thrombocythemia), Immune Thrombocytopenia, Indolent Systemic Mastocytosis

Studies at this site

• Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders — Recruiting now
• A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors — Recruiting now
• (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors — Recruiting now
• A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation — Recruiting now
• A Study of Lerociclib in Participants With Advanced Breast Cancer — Stopped early
• A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment — Completed
• Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms — Running, not enrolling
• A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) — Stopped early
• To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) — Stopped early
• IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18) — Running, not enrolling
• A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1). — Completed
• Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration — Completed
• Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis — Status unconfirmed
• A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection) — Stopped early